Table 4.

Treatment effectiveness according to regimen, calculated as per protocol analysis

Regimen	SVR PP, n (%)
All regimens	3271/3442 (95)
OBV/PTV/(r ± DSV ± RBV)	1052/1076 (97.8)
LDV/(SOF ± RBV)	748/778 (96.1)
GZR/(EBR ± RBV)	387/398 (97.2)
VEL/(SOF ± RBV)	477/521 (91.6)
GLE/PIB	420/435 (96.6)
GLE/PIB/(SOF + RBV)	2/2 (100)
ASV + DCV	47/55 (85.5)
SOF + DCV ± RBV	21/21 (100)
SOF + RBV	105/144 (72.9)
SOF + SMV ± RBV	5/5 (100)
VOX/VEL/SOF	7/7 (100)

PP: Per protocol; SVR: Sustained virological response; OBV: Ombitasvir; PTV/r: Paritaprevir; DSV: Dasabuvir; RBV: Ribavirin; LDV: Ledipasvir; SOF: Sofosbuvir; GZR: Grazoprevir; EBR: Elbasvir; VEL: Velpatasvir; GLE: Glecaprevir; PIB: Pibrentasvir; ASV: Asunaprevir; DCV: Daclatasvir; SMV: Simeprevir; VOX: Voxilaprevir.